Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134199 · ClinicalTrials.gov registry record · Phase 2
A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 282
- Enrollment target
NCT00134199: Completed Phase 2 study, sponsored by Pfizer.
NCT00134199 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 282 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134199, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 282 participants
- Enrollment target
Study Summary
To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the concentration of the drug on the blood and the above parameters * physical and psychosocial functioning, weight related symptoms, treatment satisfaction, appetite/hunger/satiety/craving and mood, anxiety, anhedonia and depression
Interventions
- DRUG CP-945,598
- DRUG sibutramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00134199 record still lists
NCT00134199 is an interventional study that assigns participants to a tested intervention. The registered 282 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (112% higher).
The record links to 0 conditions, and to 2 interventions - of which CP-945,598 is the first listed.
NCT00134199 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00134199 about?
NCT00134199 is a clinical study titled "A Study Of 6-Month Duration To Evaluate The Weight Loss Effect Of Various Doses Of CP-945,598 In Obese Subjects". To evaluate the effect of 6-month administration of CP-945,598 on: * weight loss and waist circumference, * blood pressure, cholesterol, glucose * other biochemical variables like insulin, leptin, ghrelin, adiponectin, PAI 1, TNF-α and hsCRP * the relationship between the concentration of the drug...
What is the current status of trial NCT00134199?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2005-03. Estimated completion is 2005-11.
What interventions are being tested in trial NCT00134199?
The interventions under investigation include: CP-945,598 (DRUG), sibutramine (DRUG).
Who is sponsoring clinical trial NCT00134199?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00134199's enrollment target sits among peer trials
282 195th of 2000 higher than 1,805 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02860364 · 282 participants · NA
Comparing Hypothermic Temperatures During Hemiarch Surgery
- NCT04867395 · 282 participants · NA
A Multi-Phase Study Examining Hospital to Home Transitions for Children With Medical Complexity
- NCT05101070 · 282 participants · Phase 1
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
- NCT06276491 · 282 participants · Phase 1
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia